The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic ... tezepelumab’s potential as a new treatment for patients whose lives are disrupted by ...
“If your nasal polyps get to a phase in which you have a very large and significant polyp load, it’s very hard to get them to go away,” she says. Treatment and Medication Options for Nasal ...
Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...
“The [Tezspire] data is clinically meaningful and offers patients with nasal polyps hope for a potential new treatment option that may reduce the burden on patients and healthcare systems.” Tezspire ...
Participants in the trial were symptomatic despite treatment with standard of care (intranasal corticosteroids [INCS]). Chronic rhinosinusitis with nasal polyps is a condition that can cause ...